25-vitamin D reduces inflammation in uremic environment

Imagem de Miniatura
Arquivos
art_BRITO_25vitamin_D_reduces_inflammation_in_uremic_environment_2020.PDF (1.1 MB)
Citações na Scopus
14
Tipo de produção
article
Data de publicação
2020
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
NATURE PUBLISHING GROUP
Autores
BRITO, Rodrigo Barbosa de Oliveira
REBELLO, Jacqueline Ferritto
GRABULOSA, Caren Cristina
PINTO, Walter
JR, Armando Morales
DALBONI, Maria Aparecida
Citação
SCIENTIFIC REPORTS, v.10, n.1, article ID 128, 8p, 2020
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Chronic kidney disease (CKD) is characterized by loss of renal function and a consequent increase of serum uremic toxins, which contribute to inflammation status. Deficiency of 25-vitamin D, often found in patients with CKD, has been included as an inflammatory factor since it might modulate the immune system. The aim of this study was to investigate the role of 25-vitamin D on inflammatory pathways in healthy and uremic environment. Toll-like receptor 4 (TLR4), oxidative stress (ROS), vitamin D receptor (VDR), 1-alpha hydroxylase (CYP27), 24 hydroxylase, cathelicidin, and MCP-1 were evaluated in monocytes exposed to a uremic serum pool compared with healthy pool. The human monocytes lineage (U937) was incubated with or without 25-vitamin D (50 ng/ml for 24 hours). TRL4, VDR, CYP27, CYP24, and ROS were evaluated by flow cytometry. We used ELISA to measure IL-6, TNF-alpha, IL-10, cathelicidin, and MCP-1 in the cell culture supernatant. We observed a higher expression of TRL-4, IL-6, TNF-alpha, IL-10, cathelicidin and MCP-1 in monocytes incubated with uremic serum when compared with serum from healthy individuals. Supplementation of 25-vitamin D was able to reduce the expression of TRL4, cathelicidin, and MCP-1 in the uremic environment. There was no difference in the expression of VDR, CYP27 and CYP24 intracellular enzymes. This in vitro study showed that the uremic pool activates inflammatory response in monocytes, which was reversed by 25-vitamin D supplementation; this finding suggests that 25-vitamin D has an anti-inflammatory role in the uremic environment.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/37188
Referências
  1. Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391
  2. Azevedo MLV, 2016, TOXICOL LETT, V263, P1, DOI 10.1016/j.toxlet.2016.10.006
  3. BHALLA AK, 1983, J CLIN ENDOCR METAB, V57, P1308, DOI 10.1210/jcem-57-6-1308
  4. Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027
  5. Bolati D, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-56
  6. Borges NA, 2016, J RENAL NUTR, V26, P396, DOI 10.1053/j.jrn.2016.07.005
  7. Carmona A, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00666
  8. Carvalho JTG, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179540
  9. Charytan DM, 2015, AM J KIDNEY DIS, V66, P196, DOI 10.1053/j.ajkd.2014.12.016
  10. Claro LM, 2018, TOXINS, V10, DOI 10.3390/toxins10100384
  11. da Silva FP, 2017, IMMUNOL LETT, V182, P57, DOI 10.1016/j.imlet.2017.01.004
  12. Fukami A, 2011, CLIN CARDIOL, V34, P189, DOI 10.1002/clc.20834
  13. Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
  14. Gois PHF, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081773
  15. Gombart AF, 2007, J STEROID BIOCHEM, V103, P552, DOI 10.1016/j.jsbmb.2006.12.095
  16. Grabulosa CC, 2018, EXP CELL RES, V365, P157, DOI 10.1016/j.yexcr.2018.02.022
  17. HASUI M, 1989, J IMMUNOL METHODS, V117, P53, DOI 10.1016/0022-1759(89)90118-X
  18. Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
  19. Holick MF, 2017, REV ENDOCR METAB DIS, V18, P153, DOI 10.1007/s11154-017-9424-1
  20. Jain SK, 2013, BIOCHEM BIOPH RES CO, V437, P7, DOI 10.1016/j.bbrc.2013.06.004
  21. Kaminski TW, 2017, BMC NEPHROL, V18, DOI 10.1186/s12882-017-0457-1
  22. Kim HY, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03130-z
  23. Kracht M, 2002, CYTOKINE, V20, P91, DOI 10.1006/cyto.2002.0895
  24. Lau WL, 2018, CLIN SCI, V132, P509, DOI 10.1042/CS20171107
  25. Lekawanvijit S, 2014, J PHYSIOL-LONDON, V592, P3969, DOI 10.1113/jphysiol.2014.273078
  26. Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
  27. Meireles MS, 2016, CLIN NUTR, V35, P1251, DOI 10.1016/j.clnu.2016.04.014
  28. Mousa A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15264-1
  29. Onal EM, 2019, HYPERTENS RES, V42, P123, DOI 10.1038/s41440-018-0144-z
  30. Outtz HH, 2010, J IMMUNOL, V185, P4363, DOI 10.4049/jimmunol.1000720
  31. PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008
  32. Ramanathan B, 2002, MICROBES INFECT, V4, P361, DOI 10.1016/S1286-4579(02)01549-6
  33. Rossi M, 2014, ARCH MED RES, V45, P309, DOI 10.1016/j.arcmed.2014.04.002
  34. Shimizu H, 2013, LIFE SCI, V92, P143, DOI 10.1016/j.lfs.2012.11.012
  35. Sorensen OE, 2001, BLOOD, V97, P3951, DOI 10.1182/blood.V97.12.3951
  36. Stinghen AEM, 2011, INT J HYPERTENS, DOI 10.4061/2011/232683
  37. Stockler-Pinto MB, 2018, INT UROL NEPHROL, V50, P347, DOI 10.1007/s11255-017-1748-y
  38. STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004
  39. Trojanowicz B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102137
  40. Vanholder Raymond C, 2003, Hemodial Int, V7, P156, DOI 10.1046/j.1492-7535.2003.00034.x
  41. Yang LF, 2017, J TOXICOL SCI, V42, P763, DOI 10.2131/jts.42.763
  42. Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837
  43. Zhang Y, 2012, J IMMUNOL, V188, P2127, DOI 10.4049/jimmunol.1102412

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - ODS/03